ClinicalTrials.gg
Active, not recruitingNCT07015268Updated Mar 2, 2026

A Clinical Study of KLH-2109 in Patients With Endometriosis

A Phase 3 interventional study of KLH-2109 and Leuprorelin acetate in Endometriosis, sponsored by Kissei Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in Japan. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.

Started
2025
the only one that year
Phase 3
5 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
9 of 10
Kissei Pharmaceutical Co., Ltd.

Among the 10 studies testing linzagolix in Endometriosis, this one is the only one that started in 2025, is one of 5 in phase 3, and was the 10th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →

About linzagolix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing linzagolix in Endometriosis as a file.
02

Study summary

To verify the non-inferiority of KLH-2109 to leuprorelin acetate in a double-blind manner in terms of efficacy in endometriosis patients with pelvic pain.

03

Conditions studied

  • Endometriosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Premenopausal women aged 18 years or older (at the time of consent) with endometriosis who meet any of the following inclusion criteria.:

  • A diagnosis of endometriosis by laparotomy or laparoscopy within 5 years before the start of the screening period;
  • Ovarian chocolate cyst confirmed by MRI performed within 1 year before the start of the screening period or ultrasonography (transvaginal, transabdominal, or transrectal) carried out at the start of the screening period; or
  • Any of induration of the pouch of Douglas, limitation of uterine mobility, and pelvic tenderness based on the result of pelvic/rectal examination at the start of the screening period and a diagnosis of clinical endometriosis

Exclusion criteria

Exclusion Criteria:

  1. Patients with undiagnosed abnormal genital bleeding
  2. Patients with abnormal uterine bleeding or anovulatory bleeding judged to be severe by the principal investigator or subinvestigator
  3. Patients with concomitant chronic abdominal pain not attributable to endometriosis (such as irritable bowel syndrome [IBS] and interstitial cystitis)
  4. Patients with concomitant pelvic inflammatory disease or a history of pelvic inflammatory disease within 8 weeks before obtaining
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    KLH-2109 group

    Oral administration

    Drug: KLH-2109

  • Active comparator
    Leuprorelin group

    Subcutaneous administration

    Drug: Leuprorelin acetate

Interventions

  • \- KLH-2109 tablet: Oral administration \- Leuprorelin acetate placebo: Subcutaneous administration

  • \- KLH-2109 placebo tablet: Oral administration \- Leuprorelin acetate: Subcutaneous administration

06

What researchers measure

Primary outcomes

  1. Change from baseline in the maximum NRS score for pelvic pain during 28 days prior to 12 weeks of the investigational product treatment

    NRS score for pelvic pain: The NRS score for pelvic pain is an integer scale of 0 to 10 in which the worst daily pain associated with endometriosis is scored as 0 for "no pain" and 10 for "the worst pain imaginable."

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in and actual values of the maximum NRS score for pelvic pain every 28 days

    The NRS score for pelvic pain is an integer scale of 0 to 10 in which the worst daily pain associated with endometriosis will be scored as 0 for "no pain" and 10 for "the worst pain imaginable."

    Time frame: Up to 24 weeks

  2. Change from baseline in and actual values of the maximum severity score for pelvic pain every 28 days

    The severity of pelvic pain will be assessed on a five-point scale, based on the most severe pain experienced during the day: as score 0 for "None: No pain", score 1 for "Very mild: Not bothersome, score 2 "Mild: Concerned but tolerable (not requiring analgesics), score 3 for "Moderate: Unbearable (requiring analgesics), and score 4 for "Severe: Intolerable despite the use of analgesics.

    Time frame: Up to 24 weeks

  3. Change from baseline in and actual values of severity score for temporary pain at each evaluation time point

    Pain in bowel movement will be assessed on a five-point scale: as score 0 for "None: No pain", score 1 for "Very mild: Not bothersome", score 2 "Mild: Concerned but tolerable", score 3 for "Moderate: Unbearable to continuously receive stimulation causing the pain", and score 4 for "Severe: Intolerable unless stimulation causing the pain is immediately discontinued". Pain during a pelvic examination will be assessed on a four-point scale: as score 0 for "None: No findings", score 1 for "Mild: Pelvic tenderness", score 2 for "Moderate: Between Mild and Severe", and score 3 for "Severe: Severe pelvic tenderness". Dyspareunia will be assessed on a five-point scale: as score 0 for "None: No pain", score 1 for "Very mild: Not bothersome", score 2 for "Mild: Feeling pain but tolerable", score 3 for "Moderate: Severe pain and discontinuation due to pain", and score 4 for "Severe: Unbearable severe pain and avoidance of sexual intercourse from the beginning".

    Time frame: Up to 24 weeks

  4. Change from baseline in and actual values of severity score of objective findings at each evaluation time point

    * The severity of the induration of the pouch of Douglas will be assessed on a four-point scale: as score 0 for "None: No findings", score 1 for "Mild: Presence of a small finger-sized induration", score 2 for "Moderate: Between Mild and Severe", and score 3 for "Complete occlusion of the pouch of Douglas with no elasticity". * The severity of the limitation of uterine mobility will be assessed on a four-point scale: as score 0 for "None: No findings", score 1 for "Mild: Limited mobility ", score 2 for "Moderate: Severely limited mobility", and score 3 for "Severely limited mobility, no movement at all".

    Time frame: Up to 24 weeks

  5. Percent change from baseline in and actual values of ovarian chocolate cyst volume at each evaluation time point

    The presence or absence of ovarian chocolate cyst in both ovaries will be determined by ultrasonography (transvaginal, transabdominal, or transrectal) and the long and short axes of all ovarian chocolate cysts (unit, mm) will be measured.

    Time frame: Up to 24 weeks

  6. Change from baseline in and actual values of EHP-30 domain score at each evaluation time point

    The EHP-30 is a questionnaire rating scale of 30 items related to QOL in patients with endometriosis on a 5-point scale: "Never", "rarely", "sometimes", "often" and "always". The subjects themselves will evaluate their QOL for the prior month using the EHP-30 questionnaire form and record the results of their assessment in the questionnaire form.

    Time frame: Up to 24 weeks

  7. Incidence of adverse events and treatment-related adverse events

    Time frame: Up to 24 weeks

  8. Percent change from baseline in bone mineral density at each evaluation time point

    Time frame: Up to 24 weeks

  9. Change from baseline in T-score at each evaluation time point

    The "T-score" is an important indicator used in bone density tests. It shows how much an individual's bone density deviates from the average value of young adults (YAM: Young Adult Mean) in terms of standard deviations (SD). Specifically, it is evaluated as follows: * -1.0 or above: Normal * Between -1.0 and -2.5: Low bone mass (osteopenia) * -2.5 or below: Osteoporosis

    Time frame: Up to 24 weeks

07

Study locations

1 site
  • Research Site
    Multiple Locations, Japan
08

References and documents

Individual participant data

Plan to share: Yes — The Individual Patient Data (IPD) are available upon reasonable request and with permission of Kissei Pharmaceutical Co., Ltd. For a data sharing request for IPD, please contact Kissei Pharmaceutical at rinsyousiken@pharm.kissei.co.jp.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2027, 29 months after the start.

Of 33 phase 3 interventional studies under Endometriosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's planned 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 11, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07015268
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jun 9, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Yoshitaka Shimizu
study director · Kissei Pharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion